Our Vision

Our vision is to build on the innovative research being conducted by Dr. M. Karen Newell-Rogers, by developing the technology from the laboratory stage through to clinical trials and seeking partners for late-stage clinical development. Dr. Newell-Rogers’s work in the areas of Targeted Peptides Technology (TPT) and Metabolic Disruption Technology (MDT) are revealing new facets of many diseases and the body’s response to them. In doing so, we believe that her work is outlining solutions to some of the world’s major health challenges including HIV/AIDS, drug-resistant cancers and autoimmune disease.